The
following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net
loss per share because to do so would be anti-dilutive:
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share
| | |
2025 | | |
2024 | |
| | |
For the Years Ended | |
| | |
December 31, | |
| | |
2025 | | |
2024 | |
| Warrants [1] | |
| 6,911,773 | | |
| 1,747,093 | |
| Options | |
| 387,357 | | |
| 9,612 | |
| Series A Convertible Preferred Stock | |
| 72 | | |
| 72 | |
| Series B Convertible Preferred Stock | |
| 2,067 | | |
| 2,067 | |
| Total potentially dilutive shares | |
| 7,301,269 | | |
| 1,758,844 | |
| [1] |
As
part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction
of certain milestones and, accordingly, are not included in the amount currently reported. See Note 8 - Commitments and Contingencies
- License Agreements for details. |
|